BreezeBio Establishes Scientific Advisory Board to Advance Precision Genetic Medicine Pipeline
BreezeBio, formerly known as GenEdit, has announced the formation of its inaugural Scientific Advisory Board (SAB), marking a significant step in the company’s ongoing expansion as it advances a pipeline of precision genetic medicines and broadens the capabilities of its NanoGalaxy® delivery platform. The newly established advisory board brings together prominent scientific and biotechnology leaders with expertise spanning targeted delivery technologies, immune modulation, translational medicine, therapeutic development, and clinical advancement.
The company stated that the Scientific Advisory Board will play a central role in guiding BreezeBio’s strategic and scientific priorities as it enters its next phase of growth. The advisors are expected to support the development of the company’s lead therapeutic candidate, BRZ-101, as well as additional internal programs designed around the NanoGalaxy platform.
BreezeBio Chief Executive Officer Kunwoo “Ryan” Lee emphasized that the company is transitioning into a new stage focused on translating the broad scientific potential of NanoGalaxy into a focused pipeline of precision genetic medicines. According to Lee, assembling a multidisciplinary advisory board with deep expertise in areas critical to genetic medicine development will help the company prioritize programs and accelerate innovation.
Lee explained that the advisory board’s experience across delivery technologies, immunology, therapeutic engineering, and clinical translation aligns closely with BreezeBio’s long-term objective of advancing highly targeted therapies capable of addressing serious diseases with improved precision and safety profiles. He added that the SAB’s guidance would be especially valuable as BreezeBio moves BRZ-101 toward clinical development and continues expanding the possibilities enabled by NanoGalaxy.
The company’s NanoGalaxy platform represents the technological foundation of BreezeBio’s research and development strategy. The platform is designed to achieve targeted in vivo delivery of genetic medicines to specific tissues and cell types, a challenge that remains one of the most important areas in modern biotechnology and nucleic acid therapeutics.
According to the company, NanoGalaxy has already demonstrated targeted delivery capabilities across multiple biological systems, including immune, cardiac, pulmonary, and central nervous system tissues. These results support both the company’s internal therapeutic pipeline and broader applications of the platform across multiple disease areas.
Targeted delivery technologies have become increasingly important in the development of next-generation therapies involving messenger RNA (mRNA), gene editing, oligonucleotides, and cellular engineering. One of the major challenges in these therapeutic modalities is ensuring that treatment reaches the intended cells while minimizing off-target effects and preserving overall safety.
BreezeBio believes NanoGalaxy can address these challenges through ligand-directed delivery approaches that improve cell specificity and therapeutic precision. The company is also exploring how the platform may enable new approaches to in vivo cell engineering, including future applications involving CAR-T therapies generated directly inside the body.
The company’s lead development program, BRZ-101, is currently advancing through investigational new drug (IND)-enabling studies for Type 1 Diabetes. The therapy is designed to deliver mRNA-encoded autoantigens and tolerogenic co-factors directly to antigen-presenting cells, with the goal of restoring immune tolerance rather than broadly suppressing immune function.
Type 1 diabetes is an autoimmune condition in which the immune system mistakenly attacks insulin-producing beta cells in the pancreas. Current treatment approaches primarily focus on insulin replacement and glucose management, but researchers continue searching for therapies capable of addressing the underlying autoimmune process itself.
BRZ-101 aims to intervene at the immune level by presenting disease-associated antigens to T cells in a tolerogenic context. This strategy is intended to induce antigen-specific regulatory T cells, or Tregs, which can selectively suppress the autoimmune attack responsible for disease progression while preserving broader immune activity.
The concept of antigen-specific immune tolerance has gained increasing attention within autoimmune disease research because it may offer a way to rebalance immune responses without the generalized immunosuppression associated with many traditional therapies. If successful, such approaches could potentially provide more durable disease control with fewer systemic side effects.
The formation of the Scientific Advisory Board reflects BreezeBio’s effort to strengthen scientific leadership around these complex therapeutic strategies. Each inaugural SAB member brings extensive experience in fields highly relevant to the company’s platform technologies and pipeline ambitions.
One of the newly appointed advisors is Dr. Haig Aghajanian, Adjunct Assistant Professor of Medicine at the Perelman School of Medicine. Dr. Aghajanian previously served as Co-Founder and Senior Vice President and Head of Research at Capstan Therapeutics, where he contributed to the advancement of the company’s in vivo cell-engineering platform prior to its acquisition by AbbVie.
Dr. Aghajanian’s research and industry work span several areas central to BreezeBio’s focus, including cardiac disease, fibrosis, immune-cell engineering, and targeted delivery systems. His expertise in engineering therapies capable of acting directly within the body is expected to support BreezeBio’s efforts to develop advanced in vivo genetic medicine applications.
Another member of the advisory board is Dr. Andrew M. Dahlem, who currently serves as President of Dr. Dahlem Consulting and Senior Research Professor of Medicine at the Indiana University School of Medicine. He also serves as Co-Director of the institution’s Drug Development Think Tank.
Dr. Dahlem brings extensive pharmaceutical industry experience gained during a 28-year career at Eli Lilly and Company. Throughout his tenure at Lilly, he held multiple executive leadership positions, including Vice President of Research Operations, Toxicology, Drug Metabolism, Pharmacokinetics, and Chief Operating Officer of Lilly Research Laboratories and Lilly Research Laboratories Europe.
His expertise spans translational medicine, toxicology, pharmacokinetics, operational strategy, and drug development infrastructure. These capabilities are particularly important for companies advancing complex therapeutic platforms toward regulatory and clinical milestones.
The advisory board also includes Dr. Thomas W. Dubensky Jr., President and Chief Executive Officer of ImmuneSensor Therapeutics. ImmuneSensor focuses on developing modulators of the cGAS-STING pathway for inflammatory diseases, autoimmune conditions, and oncology applications.
Dr. Dubensky has extensive experience in translational science and immunotherapy development across multiple therapeutic areas, including cancer immunotherapy, innate immunity, infectious disease therapeutics, biologics, and small-molecule drug development. His background in immune system modulation and translational biology is expected to provide valuable insight as BreezeBio develops therapies intended to selectively shape immune responses.
Completing the inaugural Scientific Advisory Board is Dr. Niren Murthy, a scientific co-founder of BreezeBio and Professor of Bioengineering at the University of California, Berkeley. He is also affiliated with the Innovative Genomics Institute.
Dr. Murthy’s research focuses on biomaterials, drug delivery systems, molecular imaging, diagnostics, and infectious disease technologies. His work includes development of next-generation delivery systems for lipid nanoparticles, RNA therapeutics, proteins, oligonucleotides, and diagnostic platforms.
His scientific contributions align closely with the underlying technology behind NanoGalaxy and the broader field of targeted nucleic acid delivery, which has emerged as one of the most transformative areas in biotechnology following advances in mRNA therapeutics and gene-editing technologies.
The establishment of the Scientific Advisory Board comes during a period of rapid growth and innovation across the genetic medicines sector. Advances in RNA delivery, gene editing, and cell-specific targeting have created new opportunities to treat diseases previously considered difficult or impossible to address using conventional pharmaceutical approaches.
However, many of these therapeutic strategies still face substantial scientific and technical hurdles, particularly in the areas of delivery specificity, durability, immune compatibility, and manufacturing scalability. Companies capable of solving these challenges may be positioned to play major roles in the next generation of precision medicine.
BreezeBio’s focus on targeted delivery and immune modulation places it within a highly competitive but rapidly expanding field that includes applications across autoimmune disease, oncology, rare diseases, and regenerative medicine. By combining proprietary delivery technologies with disease-focused therapeutic programs, the company aims to establish a differentiated position in the broader genetic medicines landscape.
The company’s emphasis on in vivo delivery strategies is especially notable because of the potential advantages over ex vivo approaches, which often involve more complex manufacturing and treatment procedures. In vivo methods may eventually enable more scalable, accessible, and cost-effective therapeutic interventions if technological challenges can be successfully addressed.
As BreezeBio continues advancing BRZ-101 toward clinical development while expanding additional applications for NanoGalaxy, the newly formed Scientific Advisory Board is expected to provide strategic scientific guidance that supports both near-term development goals and long-term platform innovation.
Through the addition of experienced leaders in biotechnology, immunology, translational medicine, and targeted delivery science, BreezeBio is positioning itself to further develop its precision genetic medicine capabilities and strengthen its efforts to bring novel therapies to patients with serious and underserved diseases.
About BreezeBio
BreezeBio is a biotechnology company developing genetic medicines enabled by precise, non-viral delivery across biologically relevant tissues. Using its proprietary NanoGalaxy® platform, BreezeBio engineers nanoparticles designed to deliver genetic payloads, including mRNA, to specific cell types, with demonstrated delivery to immune cells as well as select tissues in the heart, lung, and central nervous system. The company is advancing an internal therapeutic pipeline focused on autoimmune diseases and oncology, led by BRZ-101 to restore immune tolerance in type 1 diabetes. BreezeBio is headquartered in California in the South San Francisco area.
